HER2 Biomarkers News and reporting on HER2 biomarkers. Sep 13, 2022 Combination Trials Point to New Potential Treatment Strategies in Breast Cancer Premium Sep 11, 2022 Selective Estrogen Receptor Degraders, Modulators Show Promise in ESR1-Mutant Breast Cancer Premium Sep 10, 2022 Lilly's Verzenio Extends Five-Year Breast Cancer Survival, Adds to Debate Over Best CDK4/6 Inhibitor Sep 6, 2022 UK's MHRA Approves Adjuvant Lynparza for BRCA-Mutant, High-Risk Early Breast Cancer Sep 1, 2022 Aston Sci. to Launch Phase II US Study of Experimental Vaccine in HER2-Low Breast Cancer Patients Aug 17, 2022 Sanofi Ends Development of Breast Cancer Drug Amcenestrant Aug 16, 2022 Gilead Sciences Files for Trodelvy FDA Approval in HR-Positive Breast Cancer, Buys Rights in Asia Aug 12, 2022 AstraZeneca, Daiichi Sankyo's Enhertu Scores FDA Accelerated Approval in HER2-Mutant Lung Cancer Aug 9, 2022 GSK, Mersana Therapeutics Ink $100M Option Agreement for Antibody-Drug Conjugate Aug 5, 2022 FDA Approves Enhertu for HER2-Low Metastatic Breast Cancer Aug 4, 2022 Merck, AstraZeneca Net European Approval for Adjuvant Lynparza in BRCA-Mutated Early Breast Cancer Aug 2, 2022 Context Therapeutics, Menarini Group Collaborate on Phase I/II Breast Cancer Combo Trial Jul 29, 2022 AstraZeneca Q2 Oncology Sales Grow 14 Percent as Firm Awaits Key Precision Drug Regulatory Decisions Premium Jul 28, 2022 Pfizer Reports Q2 US Sales Growth for Ibrance Despite Declines in Other Markets, Greater Competition Premium Jul 27, 2022 Celularity Begins Trial of NK Cell Therapy, Herceptin, Keytruda for HER2-Positive Gastric Cancer Jul 19, 2022 Enhertu Racks Up Another EU Approval in Second-Line HER2-Positive Metastatic Breast Cancer Jul 19, 2022 Kisqali Shines as Novartis Posts Slight Decline in Q2 Revenues Jul 18, 2022 Byondis, Medac File for European Approval of SYD985 for HER2-Positive Breast Cancer Jul 11, 2022 HER2-Low Response Data Spurs Paige to Develop New Breast Cancer Pathology Test Premium Jun 27, 2022 EMA's CHMP Backs Approval for Enhertu, Lynparza for Two Breast Cancer Indications Load More Breaking News FDA Approves Taiho Oncology's Lytgobi for FGFR2-Rearranged Bile Duct Cancer Gladstone Institute Joins With Parker Institute on New Center to Study CRISPR-Based Cell Therapies Meliora Therapeutics Raises $11M in Seed Financing In Brief This Week:Â Verismo Therapeutics, Fore Biotherapeutics, Merck, Caris Life Sciences Tumor-Only Sequencing Found to Overestimate Mutational Burden in Non-European Patients Atara Biotherapeutics to Net $30M From Pierre Fabre for European Tab-Cel Approval
